Exercise of the over-allotment option in relation to shares of series B in Recipharm

NOT FOR RELEASE IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, NEW ZEALAND,
SOUTH AFRICA OR THE UNITED STATES.

Further to the announcement by Recipharm AB (publ) (“Recipharm” or the
“Company”) on 3 April, 2014, Recipharm today confirms that, in connection with
its initial public offering, Carnegie Investment Bank AB (publ) and
SkandinaviskaEnskildaBanken AB (publ) have exercised the over-allotment option
in full in respect of 2,517,884 existing shares of series B in Recipharm.
Following the exercise of the over-allotment option, the main owners Lars
Backsell and Thomas
Eldered[1] (http://file///C:/Users/nili/AppData/Local/Microsoft/Windows/Temporar
y 
%20Internet%20Files/Low/Content.IE5/TUXECHXU/Projekt_Starlight_
-_Excercise_of_over-allotment_opiton_(ENG)%5b1%5d.docx#_ftn1), will hold
16,578,123
shares[2] (http://file///C:/Users/nili/AppData/Local/Microsoft/Windows/Temporary
% 
20Internet%20Files/Low/Content.IE5/TUXECHXU/Projekt_Starlight_
-_Excercise_of_over-allotment_opiton_(ENG)%5b1%5d.docx#_ftn2) in Recipharm,
corresponding toapproximately 45 percent of the shares and approximately 86
percent of the votes in the
Company[3] (http://file///C:/Users/nili/AppData/Local/Microsoft/Windows/Temporar
y 
%20Internet%20Files/Low/Content.IE5/TUXECHXU/Projekt_Starlight_
-_Excercise_of_over-allotment_opiton_(ENG)%5b1%5d.docx#_ftn3).

The banks have also notified Recipharm that the stabilisation period in respect
of the offer has ended today and confirmed that there have not been any
stabilisation transactions in respect of the offer.

For further information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, thomas.eldered@recipharm.com, telephone: +46 8 602 52 10
Björn Westberg, CFO, bjorn.westberg@recipharm.com, telephone: +46 8 602 46 20

This information is in accordance with the Swedish Securities Market Act, the
Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ OMX
Stockholm. This information was submitted for publication on 11 April, 2014, at
07.30 CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry based in Sweden employing some
1,500 employees. Recipharm offers manufacturing services of pharmaceuticals in
various dosage forms, production of clinical trial material and pharmaceutical
product development. Recipharm currently manufactures more than 200 different
products to both Big Pharma and smaller research- and development companies.
Recipharm’s turnover is approximately SEK 2.1 billion and the Company operates
development and manufacturing facilities in Sweden, France, the UK, Germany and
Spain and is headquartered near Stockholm.
For more information on Recipharm and our services, please visit
www.recipharm.com.

Important information
This announcement is not an offer to sell or a solicitation of any offer to buy
any securities issued by Recipharm in any jurisdiction where such offer or sale
would be unlawful.

In any EEA Member State, other than Sweden, that has implemented Directive
2003/71/EC as amended (together with any applicable implementing measures in any
member State, the “Prospectus Directive”), this communication is only addressed
to and is only directed at qualified investors in that Member State within the
meaning of the Prospectus Directive.

Any securities referred to herein have not been and will not be registered under
the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not
be offered or sold in the United States absent registration or an exemption from
registration under the Securities Act.  There is no intention to register any
securities referred to herein in the United States or to make a public offering
of the securities in the United States.  Any securities sold in the United
States will be sold only to qualified institutional buyers (as defined in Rule
144A under the Securities Act) pursuant to Rule 144A.

In the United Kingdom, this document and any other materials in relation to the
securities described herein is only being distributed to, and is only directed
at, and any investment or investment activity to which this document relates is
available only to, and will be engaged in only with, “qualified investors” (as
defined in section 86(7) of the Financial Services and Markets Act 2000) and who
are (i) persons having professional experience in matters relating to
investments who fall within the definition of “investment professionals” in
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling
within Article 49(2)(a) to (d) of the Order (all such persons together being
referred to as “relevant persons”).  Persons who are not relevant persons should
not take any action on the basis of this document and should not act or rely on
it.

----------------------------------------------------------------------

[ (http://file///C:/Users/nili/AppData/Local/Microsoft/Windows/Temporary%20Inter
n 
et%20Files/Low/Content.IE5/TUXECHXU/Projekt_Starlight_-_Excercise_of_over
-allotment_opiton_(ENG)%5b1%5d.docx#_ftnref1)1] (http://file///C:/Users/nili/App
D 
ata/Local/Microsoft/Windows/Temporary%20Internet%20Files/Low/Content.IE5/TUXECHX
U 
/Projekt_Starlight_-_Excercise_of_over
-allotment_opiton_(ENG)%5b1%5d.docx#_ftnref1)Through the company B&E
Participation AB.
[2] (http://file///C:/Users/nili/AppData/Local/Microsoft/Windows/Temporary%20Int
e 
rnet%20Files/Low/Content.IE5/TUXECHXU/Projekt_Starlight_-_Excercise_of_over
-allotment_opiton_(ENG)%5b1%5d.docx#_ftnref2) Whereof 3,892,407 shares of series
B and 12,685,716 shares of series A.
[3] (http://file///C:/Users/nili/AppData/Local/Microsoft/Windows/Temporary%20Int
e 
rnet%20Files/Low/Content.IE5/TUXECHXU/Projekt_Starlight_-_Excercise_of_over
-allotment_opiton_(ENG)%5b1%5d.docx#_ftnref3)The calculation also includes
1,367,097 shares of series B which has been added through conversion of the
Company’s convertible bond programme with the last day of conversion as of 5
April, 2014.

Recipharm AB (publ)
Corporate identity number 556498-4825
Streetaddress Lagervägen 7, JordbroTelephone+46 8 602 52 00
Postal address Lagervägen 7, SE-136 50 Jordbro Fax +46 8 81 87 03
www.recipharm.com